OBJECTIVES: Using synchronized cultures of Plasmodium falciparum, the time- and concentration-dependent growth changes of erythrocytic parasite stages to DB75, piperaquine, OZ277 and OZ401 were investigated in vitro over a concentration range of approximately 1-100x the IC(50) of piperaquine, OZ277 and OZ401 and approximately 10-1000x the IC(50) of DB75. METHODS: The effects of timed in vitro exposure (1, 6, 12 or 24 h) were monitored by the incorporation of [(3)H]hypoxanthine into the parasite nucleic acids. RESULTS: After 1 h of exposure to the highest concentration of the compound followed by removal of the compound, the growth of all stages of P. falciparum was reduced to < 34% for DB75 and 15% for piperaquine, OZ277 and OZ401 compared with untreated control parasites. At this time point, no stage-specific effects were observed at any of the concentrations. Strong inhibition (< or = 10% growth) of all parasite stages was observed when the parasites were exposed to 10x or 100x the IC(50) of OZ277 and OZ401 for > or = 6 h. At the 6 h incubation time point, DB75 was more active against mature parasite stages, with the IC(50)s of young ring forms elevated up to 7-fold. This trend was observed up to 12 h, but was only statistically significant at the lowest concentration. Interestingly, the stage-specific effect of DB75 on ring forms was not detectable when washing procedures were omitted. This indicates a cytostatic action of DB75 on P. falciparum ring forms. CONCLUSIONS: The current study suggests that P. falciparum ring stages are less susceptible to DB75. A milder and often statistically insignificant stage-specific trend was observed for piperaquine, whereas OZ277 and OZ401 were equally active against the erythrocytic parasite stages.
OBJECTIVES: Using synchronized cultures of Plasmodium falciparum, the time- and concentration-dependent growth changes of erythrocytic parasite stages to DB75, piperaquine, OZ277 and OZ401 were investigated in vitro over a concentration range of approximately 1-100x the IC(50) of piperaquine, OZ277 and OZ401 and approximately 10-1000x the IC(50) of DB75. METHODS: The effects of timed in vitro exposure (1, 6, 12 or 24 h) were monitored by the incorporation of [(3)H]hypoxanthine into the parasite nucleic acids. RESULTS: After 1 h of exposure to the highest concentration of the compound followed by removal of the compound, the growth of all stages of P. falciparum was reduced to < 34% for DB75 and 15% for piperaquine, OZ277 and OZ401 compared with untreated control parasites. At this time point, no stage-specific effects were observed at any of the concentrations. Strong inhibition (< or = 10% growth) of all parasite stages was observed when the parasites were exposed to 10x or 100x the IC(50) of OZ277 and OZ401 for > or = 6 h. At the 6 h incubation time point, DB75 was more active against mature parasite stages, with the IC(50)s of young ring forms elevated up to 7-fold. This trend was observed up to 12 h, but was only statistically significant at the lowest concentration. Interestingly, the stage-specific effect of DB75 on ring forms was not detectable when washing procedures were omitted. This indicates a cytostatic action of DB75 on P. falciparum ring forms. CONCLUSIONS: The current study suggests that P. falciparum ring stages are less susceptible to DB75. A milder and often statistically insignificant stage-specific trend was observed for piperaquine, whereas OZ277 and OZ401 were equally active against the erythrocytic parasite stages.
Authors: Ralf Brunner; Caroline L Ng; Hamed Aissaoui; Myles H Akabas; Christoph Boss; Reto Brun; Paul S Callaghan; Olivier Corminboeuf; David A Fidock; Ithiel J Frame; Bibia Heidmann; Amélie Le Bihan; Paul Jenö; Corinna Mattheis; Suzette Moes; Ingrid B Müller; Michelle Paguio; Paul D Roepe; Romain Siegrist; Till Voss; Richard W D Welford; Sergio Wittlin; Christoph Binkert Journal: J Biol Chem Date: 2013-06-10 Impact factor: 5.157
Authors: Susan A Charman; Darren J Creek; Carlo Giannangelo; Lukas Stingelin; Tuo Yang; Leann Tilley Journal: Antimicrob Agents Chemother Date: 2018-02-23 Impact factor: 5.191
Authors: Susan A Charman; Sarah Arbe-Barnes; Ian C Bathurst; Reto Brun; Michael Campbell; William N Charman; Francis C K Chiu; Jacques Chollet; J Carl Craft; Darren J Creek; Yuxiang Dong; Hugues Matile; Melanie Maurer; Julia Morizzi; Tien Nguyen; Petros Papastogiannidis; Christian Scheurer; David M Shackleford; Kamaraj Sriraghavan; Lukas Stingelin; Yuanqing Tang; Heinrich Urwyler; Xiaofang Wang; Karen L White; Sergio Wittlin; Lin Zhou; Jonathan L Vennerstrom Journal: Proc Natl Acad Sci U S A Date: 2011-02-07 Impact factor: 11.205
Authors: Jutta Marfurt; Ferryanto Chalfein; Pak Prayoga; Frans Wabiser; Grennady Wirjanata; Boni Sebayang; Kim A Piera; Sergio Wittlin; Richard K Haynes; Jörg J Möhrle; Nicholas M Anstey; Enny Kenangalem; Ric N Price Journal: Antimicrob Agents Chemother Date: 2012-07-30 Impact factor: 5.191
Authors: Amalia Z Berna; James S McCarthy; Rosalind X Wang; Kevin J Saliba; Florence G Bravo; Julie Cassells; Benjamin Padovan; Stephen C Trowell Journal: J Infect Dis Date: 2015-03-25 Impact factor: 5.226
Authors: Sarah Schleiferböck; Christian Scheurer; Masataka Ihara; Isamu Itoh; Ian Bathurst; Jeremy N Burrows; Pascal Fantauzzi; Julie Lotharius; Susan A Charman; Julia Morizzi; David M Shackleford; Karen L White; Reto Brun; Sergio Wittlin Journal: Drug Des Devel Ther Date: 2013-11-15 Impact factor: 4.162
Authors: Claire Le Manach; Christian Scheurer; Sibylle Sax; Sarah Schleiferböck; Diego Gonzalez Cabrera; Yassir Younis; Tanya Paquet; Leslie Street; Peter Smith; Xavier C Ding; David Waterson; Michael J Witty; Didier Leroy; Kelly Chibale; Sergio Wittlin Journal: Malar J Date: 2013-11-16 Impact factor: 2.979